Design, Synthesis, and Pharmacological Evaluation of Monocyclic Pyrimidinones as Novel Inhibitors of PDE5

Cyclic nucleotide phosphodiesterase type 5 (PDE5) is a prime drug target for treating the diseases associated with a lower level of the cyclic guanosine monophosphate (cGMP), which is a specific substrate for PDE5 hydrolysis. Here we report a series of novel PDE5 inhibitors with the new scaffold of...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medicinal chemistry 2012-12, Vol.55 (23), p.10540-10550
Hauptverfasser:	Wang, Guan, Liu, Zheng, Chen, Tiantian, Wang, Zhen, Yang, Huaiyu, Zheng, Mingyue, Ren, Jing, Tian, Guanghui, Yang, Xiaojun, Li, Li, Li, Jianfeng, Suo, Jin, Zhang, Rongxia, Jiang, Xiangrui, Terrett, Nicholas Kenneth, Shen, Jingshan, Xu, Yechun, Jiang, Hualiang
Format:	Artikel
Sprache:	eng
Schlagworte:	Catalytic Domain Cyclic Nucleotide Phosphodiesterases, Type 5 - chemistry Cyclic Nucleotide Phosphodiesterases, Type 5 - drug effects Drug Design Inhibitory Concentration 50 Magnetic Resonance Spectroscopy Models, Molecular Phosphodiesterase Inhibitors - chemical synthesis Phosphodiesterase Inhibitors - chemistry Phosphodiesterase Inhibitors - pharmacology Pyrimidinones - chemical synthesis Pyrimidinones - chemistry Pyrimidinones - pharmacology Spectrometry, Mass, Electrospray Ionization Structure-Activity Relationship
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!